Medindia
Medindia LOGIN REGISTER
Advertisement

REVOLUTION Medicines Announces Dosing of First Patient in RMC-4630-02, a Phase 1b/2 Trial Combining RMC-4630 with a MEK Inhibitor

Tuesday, September 17, 2019 General News
Advertisement
Combination Inhibits Upstream and Downstream Targets in Oncogenic RAS Signaling Pathway, Offering Potential for Synergistic Anti-Tumor Benefit

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close